ArticleJournal of cardiovascular translational research2022
Impaired Endothelial Glycocalyx Predicts Adverse Outcome in Subjects Without Overt Cardiovascular Disease: a 6-Year Follow-up Study.
Article in Journal of cardiovascular translational research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04646252 (Impaired Endothelial Glycocalyx Predicts Adverse Outcome in Subjects Without Overt Cardiovascular Disease), which is not on this map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Impaired Endothelial Glycocalyx Predicts Adverse Outcome in Subjects Without Overt Cardiovascular Disease: a 6 Year Follow up Study
Who cites it
18 citing papers in PubMed, 28 citations in OpenAlex.
- Effects of 4-month treatment with glycocalyx dietary supplement on endothelial glycocalyx and vascular function after COVID-19 infection.European journal of clinical investigation · 2025Trial
- Sex differences in endothelial glycocalyx thickness and the response to glycocalyx-targeted therapy among older adults.Physiological reports · 2025Trial
- Trial
- Effect of glycocalyx-targeted therapy on vascular function in older adults: a randomized controlled trial.Journal of applied physiology (Bethesda, Md. : 1985) · 2024Trial
- Effects of Nutritional Supplements on Vascular Function: A Narrative Review.Journal of clinical medicine · 2026Review
- The Role of Endothelial Glycocalyx in the Pathophysiology of Chronic Kidney Disease and Hypertension: From Molecular Mechanisms to Clinical Biomarkers.Life (Basel, Switzerland) · 2026Review
- Vascular and Myocardial Function in Patients with Type 2 Diabetes and Ischemic Stroke Treated with Dulaglutide or Empagliflozin.Medicina (Kaunas, Lithuania) · 2026Observational
- Insights into the Molecular Mechanism of Endothelial Glycocalyx Dysfunction during Heart Surgery.Current issues in molecular biology · 2024Review
- Effect of acute heparin administration on glycocalyx thickness and endothelial function in healthy younger adults.Journal of applied physiology (Bethesda, Md. : 1985) · 2024Article
- Factors influencing glycocalyx degradation: a narrative review.Frontiers in immunology · 2024Review
- Endothelial Glycocalyx in Aging and Age-related Diseases.Aging and disease · 2023Review
- Reply to "The Predictive Role of Glycocalyx Assessment in Subjects with Cardiovascular Risk Factors Within and Beyond SCORE".Journal of cardiovascular translational research · 2023Article
- Biomarkers of Endothelial Glycocalyx Integrity for Cardiovascular Events in Individuals Without Cardiovascular Disease.Journal of cardiovascular translational research · 2023Article
- Endothelial Damage and the Microcirculation in Critical Illness.Biomedicines · 2022Review
- Endothelial Dysfunction Is Associated with Decreased Nitric Oxide Bioavailability in Dysglycaemic Subjects and First-Degree Relatives of Type 2 Diabetic Patients.Journal of clinical medicine · 2022Article
- Myocardial work and vascular dysfunction are partially improved at 12 months after COVID-19 infection.European journal of heart failure · 2022Article
- Apremilast Improves Endothelial Glycocalyx Integrity, Vascular and Left Ventricular Myocardial Function in Psoriasis.Pharmaceuticals (Basel, Switzerland) · 2022Article
- A randomized, placebo-controlled crossover trial to assess the influence of body weight on aspirin-triggered specialized pro-resolving mediators: Protocol for the DISCOVER Study.International journal of clinical trialsArticle
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
19 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We investigated whether disturbance of glycocalyx integrity is related with increased cardiovascular risk. In 600 healthy subjects, we measured perfused boundary region (PBR), a marker of glycocalyx integrity, in sublingual microvessels with diameter ranging 5-25 µm using a dedicated camera (Sideview Darkfield Imaging). Increased PBR indicates reduced glycocalyx thickness. We prospectively monitored the occurrence of cardiovascular events (MACE-death, myocardial infarction, and stroke) during a 6-year follow-up. Fifty-seven MACE were documented. Increased values of PBR5-25 predicted higher risk for MACE in a model including sex, age, hyperlipidemia, diabetes, hypertension, smoking, family history of coronary disease, treatment with ACEi/ARBs, or lipid-lowering agents (hazard ratio (HR), 6.44, p = 0.011; net reclassification improvement (NRI), 28%; C-statistic: 0.761). PBR5-25 was an independent and additive predictor of outcome when added in a model including the European Heart SCORE, diabetes, family history of CAD, and medication (HR, 4.71; NRI: 39.7%, C-statistic from 0.653 to 0.693; p < 0.01).Glycocalyx integrity is an independent and additive predictor to risk factors for MACE at 6-year follow-up in individuals without cardiovascular disease. ClinicalTrials.govIdentifier:NCT04646252. PBR5-25 was an independent and additive predictor of adverse cardiovascular events in a model including the European Heart SCORE, diabetes, family history of coronary disease, and medication (HR: 4.71, NRI: 39.7%, C-statistic from 0.653 to 0.693; p < 0.01, NRI:37.9%).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.